Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Xenon Pharmaceuticals Inc. Director's Dealing 2021

Jun 4, 2021

31373_dirs_2021-06-03_a7e09a99-fef6-43c2-82a9-190bab3f950d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-06-03

Reporting Person: Machado Patrick (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-03 Stock Option (Right to Buy) $18.56 A 10000 Acquired 2031-06-02 Common Shares (10000) Direct

Footnotes

F1: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to
the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year
anniversary of the grant date.